Vaxcyte, Inc. (PCVX)
71.38
+6.36
(+9.79%)
USD |
NASDAQ |
Oct 09, 16:00
71.27
-0.11
(-0.15%)
After-Hours: 20:00
Vaxcyte Cash from Investing (Quarterly) : 147.72M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 147.72M |
| March 31, 2026 | -233.41M |
| December 31, 2025 | 115.12M |
| September 30, 2025 | 121.17M |
| June 30, 2025 | 77.74M |
| March 31, 2025 | 123.32M |
| December 31, 2024 | -557.17M |
| September 30, 2024 | -917.02M |
| June 30, 2024 | -80.41M |
| March 31, 2024 | -451.07M |
| December 31, 2023 | -13.93M |
| September 30, 2023 | 22.28M |
| June 30, 2023 | -333.56M |
| March 31, 2023 | -448.10M |
| December 31, 2022 | -35.95M |
| Date | Value |
|---|---|
| September 30, 2022 | 34.71M |
| June 30, 2022 | 26.16M |
| March 31, 2022 | 49.67M |
| December 31, 2021 | 0.082M |
| September 30, 2021 | -18.47M |
| June 30, 2021 | -20.53M |
| March 31, 2021 | -173.39M |
| December 31, 2020 | -0.722M |
| September 30, 2020 | 0.021M |
| June 30, 2020 | -0.055M |
| March 31, 2020 | -0.349M |
| December 31, 2019 | -0.953M |
| September 30, 2019 | -0.06M |
| June 30, 2019 | -0.166M |
| March 31, 2019 | -0.016M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Moderna, Inc. | 329.00M |
| Vir Biotechnology, Inc. | -197.14M |
| Revolution Medicines, Inc. | -1.659B |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -232.47M |
| Cash from Financing (Quarterly) | 5.701M |
| Free Cash Flow | -921.07M |
| Free Cash Flow Per Share (Quarterly) | -1.640 |
| Free Cash Flow to Equity (Quarterly) | -236.19M |
| Free Cash Flow to Firm (Quarterly) | -237.04M |
| Free Cash Flow Yield | -9.36% |